Ceritinib (LDK378): A potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer

Clinical Lung Cancer

Volumn 16, Issue 2, 2015, Pages 86-91

  Li, Sen ^a   Qi, Xiaolong ^b   Huang, Yufeng ^c   Liu, Dingfeng ^b   Zhou, Fangyu ^b   Zhou, Caicun ^b  

^a SOUTHWEST MEDICAL UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c JINGJIANG PEOPLE'S HOSPITAL   (China)

Author keywords

ALK inhibitor; Clinical trial; Cost effectiveness; Pharmacokinetics; Resistance

Indexed keywords

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESEARCH; CANCER RESISTANCE; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; IC50; NON SMALL CELL LUNG CANCER; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; DRUG RESISTANCE; GENE REARRANGEMENT; GENETICS; HUMAN; LUNG NEOPLASMS; PATHOLOGY;

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; CERITINIB; CRIZOTINIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SULFONE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SULFONES;

EID: 84923013946     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2014.09.011     Document Type: Review

References (36)

1. R. Siegel, J. Ma, and Z. Zou Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
2. A.T. Shaw, and J.A. Engelman ALK in lung cancer: past, present, and future J Clin Oncol 31 2013 1105 1111
3. A.T. Shaw, D.W. Kim, and R. Mehra Ceritinib in ALK-rearranged non-small-cell lung cancer N Engl J Med 370 2014 1189 1197
4. J.E. Frampton Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small-cell lung cancer Drugs 73 2013 2031 2051
5. C. Gridelli, S. Peters, and A. Sgambato ALK inhibitors in the treatment of advanced NSCLC Cancer Treat Rev 40 2014 300 306
6. + non-small-cell lung cancer? Clin Lung Cancer 15 2014 313 319
7. C.E. Steuer, and S.S. Ramalingam ALK-positive non-small-cell lung cancer: mechanisms of resistance and emerging treatment options Cancer 120 2014 2392 2402
8. L. Friboulet, N. Li, and R. Katayama The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small-cell lung cancer Cancer Discov 4 2014 662 673
9. A.T. Shaw, D.W. Kim, and K. Nakagawa Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2013 2385 2394
10. T. Mok, D.W. Kim, and Y.L. Wu First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients with advanced ALK-positive non-squamous non-small-cell lung cancer: results of a phase III study (PROFILE 1014) J Clin Oncol 32 suppl 2014 5s (abstract 8002)
11. A. Timm, and J.M. Kolesar Crizotinib for the treatment of non-small-cell lung cancer Am J Health Syst Pharm 70 2013 943 947
12. R. Katayama, T.M. Khan, and C. Benes Therapeutic strategies to overcome crizotinib resistance in non-small-cell lung cancers harboring the fusion oncogene EML4-ALK Proc Natl Acad Sci U S A 108 2011 7535 7540
13. R. Katayama, A.T. Shaw, and T.M. Khan Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers Sci Transl Med 4 2012 120ra17
14. Y. Kobayashi, Y. Sakao, and S. Ito Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies J Thorac Oncol 8 2013 e75 e78
15. C. Rolfo, F. Passiglia, and A. Russo Looking for a new panacea in ALK-rearranged NSCLC: may be ceritinib? Expert Opin Ther Targets 18 2014 983 985
16. R.J. Kelly, B.E. Hillner, and T.J. Smith Cost effectiveness of crizotinib for anaplastic lymphoma kinase-positive, non-small-cell lung cancer: who is going to blink at the cost? J Clin Oncol 32 2014 983 985
17. S. Djalalov, J. Beca, and J.S. Hoch Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer J Clin Oncol 32 2014 1012 1019
18. A.J. Atherly, and D.R. Camidge The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers Br J Cancer 106 2012 1100 1106
19. M.D. Rawlins NICE: moving onward N Engl J Med 369 2013 3 5
20. H.M. Kantarjian, T. Fojo, and M. Mathisen Cancer drugs in the United States: Justum Pretium-the just price J Clin Oncol 31 2013 3600 3604
21. S.S. Ramalingam, and F.R. Khuri Second-generation ALK inhibitors: filling the non "MET" gap Cancer Discov 4 2014 634 636
22. Ceritinib gains FDA approval for lung cancer Cancer Discov 4 2014 753 754
23. T.H. Marsilje, W. Pei, and B. Chen Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials J Med Chem 56 2013 5675 5690
24. J. Chen, C. Jiang, and S. Wang LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor J Med Chem 56 2013 5673 5674
25. R.K. Thomas Overcoming drug resistance in ALK-rearranged lung cancer N Engl J Med 370 2014 1250 1251
26. Katayama R, Friboulet L, Koike S, et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res [e-pud ahead of print]. Accessed September 16, 2014. http://dx.doi.org/10.1158/1078-0432.CCR-14-1511.
27. M.M. Goldenberg Pharmaceutical approval update P T 39 2014 481 520
28. Z. Chen, E. Akbay, and O. Mikse Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance Clin Cancer Res 20 2014 1204 1211
29. A.V. Galkin, J.S. Melnick, and S. Kim Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK Proc Natl Acad Sci U S A 104 2007 270 275
30. C.A. Perez, M. Velez, and L.E. Raez Overcoming the resistance to crizotinib in patients with non-small-cell lung cancer harboring EML4/ALK translocation Lung Cancer 84 2014 110 115
31. V.A. Miller, V. Hirsh, and J. Cadranel Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial Lancet Oncol 13 2012 528 538
32. L.V. Sequist, B. Besse, and T.J. Lynch Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer J Clin Oncol 28 2010 3076 3083
33. A. Campbell, K.L. Reckamp, and D.R. Camidge PF-00299804 patient reported outcomes and efficacy in adenocarcinoma and nonadeno non-small-cell lung cancer: a phase II trial in advanced NSCLC after failure of chemotherapy and erlotinib J Clin Oncol 28 suppl 2010 15 (abstract 7596)
34. D.W. Kim, R. Mehra, and D.S.W. Tan Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small-cell lung cancer (NSCLC): Results of the ASCEND-1 trial J Clin Oncol 32 suppl 2014 5s (abstract 8003)
35. D.R. Camidge, Y.J. Bang, and E.L. Kwak Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncol 13 2012 1011 1019
36. R. Sundar, R. Soong, and B.C. Cho Immunotherapy in the treatment of non-small-cell lung cancer Lung Cancer 85 2014 101 109